ZIM Laboratories Limited share price

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: ZIMLABISIN INE518E01015

16 Oct 2026, 3:29 PM IST₹144.76▲ 4.46 (3.18%)

Market Cap₹ 775 Cr.
Current Price₹ 144.76
High / Low₹ 160 / 59
Stock P/E176.5
Book Value₹ 55
Dividend Yield0.00 %
ROCE5.8 %
ROE2.10 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 0.82
Price / Book2.62
OPM3.1 %
Debt / Equity0.43
Sales growth (3Y)-2.1 %
Profit growth (3Y)-37.9 %
Promoter holding71.2 %
EV / EBITDA38.4
Beta0.82
All-time high₹ 160

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
ZIMLAB	+5.83%	+17.72%	+90.62%	+100.64%	+109.49%	+6.05%	—
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

ZIM Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹775 crore.
It trades at 176.5 times its last 12 months' earnings and 2.6 times book value.
Revenue grew -2.1% a year over the last 3 years, profit -37.9% a year.
Return on equity was 2.1% and return on capital employed 5.8% in the latest year.
Debt was 0.43 times shareholders' equity.
The share price is 9.4% below its 52-week high and up 109.5% over one year.
Promoters and insiders hold about 71.2%; institutions about 1.2%.

Pros

No standout strengths in the reported figures.

Cons

Return on equity has been low: 5.0% on average over the last 3 years.
Interest cover is thin: operating earnings are 1.4 times the interest cost.
Sales growth has been slow: -2.1% a year over the last 3 years.
Profit growth has been weak: -37.9% a year over the last 3 years.
Promoter holding has fallen by 2.96 points over 3 years, to 30.30%.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About ZIM Laboratories Limited

Employees: 632
Head office: Nagpur

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	ZIM Laboratories	144.76	176.5	775	0.00	-4	—	94	31.25	5.8	2.1	2.62	3.1	0.43	71.23	374	-2.1
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 52 Co.	1,712.85	31.8	14,926	0.32	680	14.29	6,020	18.81	14.6	13.4	4.02	15.7	0.30	55.20	20,499	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	67	86	96	118	82	92	96	109	72	89	109	105	94
YOY Sales Growth %			-4.63%	11.81%	21.32%	7.36%	0.04%	-7.75%	-12.30%	-3.72%	12.80%	-3.18%	31.25%
	63	77	85	102	74	83	85	94	67	83	96	98	92
Material Cost %	46%	47%	46%	48%	44%	46%	43%	44%	42%	45%	45%	45%	42%
Employee Cost %	19%	15%	14%	12%	18%	17%	15%	15%	20%	18%	14%	17%	20%
Other Expenses %	28%	28%	28%	27%	28%	27%	30%	27%	32%	30%	29%	32%	35%
Operating Profit	5	9	12	16	8	10	12	15	4	6	13	7	2
OPM %	7%	11%	12%	13%	10%	10%	12%	13%	6%	6%	12%	7%	3%
Other Income	1	1	1	2	1	1	2	2	1	2	2	6	1
Interest	2	1	2	2	3	3	3	3	3	3	3	3	4
Depreciation	4	4	4	4	5	5	5	5	5	5	5	5	5
Profit before tax	0	5	7	11	1	3	6	8	-2	-0	6	5	-6
	-22%	24%	32%	26%	27%	20%	30%	40%			27%	24%
Current tax	0	1	1	-1	0	0	1	3	0	0	1	2	0
Deferred tax	-0	0	1	4	0	0	1	-0	-1	0	0	-1	-2
	0	4	5	8	1	2	4	5	-2	-0	4	4	-4
Minority share				-0				-0			-0	0	-0
Profit to shareholders	0	4	5	8	1	2	4	5	-2	-0	4	4	-4
YOY Profit Growth %			-27.51%	11.74%	296.43%	-42.61%	-16.38%	-39.59%	-308.72%	-117.83%	9.92%	-23.43%
EPS in Rs	0.05	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	67	85	96	117	82	90	95	109	71	88	108	103	93
YOY Sales Growth %			-4.48%	12.39%	22.38%	5.23%	-0.44%	-7.56%	-12.90%	-1.48%	13.01%	-5.22%	30.27%
	62	76	85	102	74	81	84	93	67	82	95	96	91
Material Cost %	46%	47%	46%	48%	45%	46%	43%	44%	42%	45%	45%	45%	42%
Employee Cost %	18%	14%	13%	12%	16%	16%	14%	14%	19%	17%	14%	16%	19%
Other Expenses %	29%	28%	29%	27%	29%	28%	31%	27%	33%	31%	29%	33%	36%
Operating Profit	5	9	11	15	8	8	12	15	4	6	12	7	2
OPM %	7%	11%	12%	13%	10%	9%	12%	14%	6%	7%	12%	6%	3%
Other Income	1	1	1	2	1	1	2	2	1	2	2	6	1
Interest	2	1	2	2	3	3	3	3	3	3	3	3	4
Depreciation	4	4	4	4	5	5	5	5	5	5	5	5	5
Profit before tax	-0	5	7	11	1	2	6	9	-2	0	6	5	-5
		23%	31%	27%	30%	34%	28%	37%		49%	28%	27%
Current tax		1	1	-1	0	0	1	3			1	2
Deferred tax	-0	0	1	4	0	0	1	-0	-1	0	0	-1	-2
	-0	4	5	8	1	1	4	5	-2	0	4	3	-4
YOY Profit Growth %			-26.50%	10.51%		-70.90%	-9.97%	-31.30%	-322.91%	-90.46%	-2.06%	-39.45%
EPS in Rs	-0.03	0.86	0.99	1.62	0.16	0.25	0.89	1.11	-0.35	0.03	0.87	0.67	-0.72
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	399	367	379	374	397
YOY Sales Growth %		-7.80%	3.16%	-1.22%
	347	326	335	344	369
Material Cost %	50%	47%	44%	44%	44%
Employee Cost %	12%	15%	16%	17%	17%
Other Expenses %	25%	28%	28%	31%	32%
Operating Profit	52	41	44	30	28
OPM %	13%	11%	12%	8%	7%
Other Income	6	5	6	11	11
Interest	6	7	11	13	14
Depreciation	17	16	20	20	20
Profit before tax	35	24	18	8	5
	31%	27%	32%	29%	27%
Current tax	6	1	5	3
Deferred tax	5	5	1	-1
	24	17	12	6	4
Minority share		-0	-0		-0
Profit to shareholders	24	17	12	6	4
YOY Profit Growth %		-29.42%	-29.46%	-52.01%
EPS in Rs	5.01	3.54	2.50	1.19	0.82
Dividend Payout %	0%	0%	0%	1%

Compounded Sales Growth

3 Years:: -2%
TTM:: 8%

Compounded Profit Growth

3 Years:: -38%
TTM:: -61%

Stock Price CAGR

3 Years:: 6%
1 Year:: 109%

Return on Equity

4 Years:: 7%
Last Year:: 2%

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	397	365	376	370	392
YOY Sales Growth %		-7.83%	2.78%	-1.37%
	345	325	332	341	364
Material Cost %	50%	47%	45%	44%	44%
Employee Cost %	12%	14%	15%	16%	16%
Other Expenses %	25%	28%	29%	31%	32%
Operating Profit	51	40	43	30	28
OPM %	13%	11%	12%	8%	7%
Other Income	6	5	6	11	11
Interest	6	7	11	13	14
Depreciation	16	15	20	19	20
Profit before tax	36	23	18	8	5
	30%	27%	33%	29%	28%
Current tax	6	1	4	3
Deferred tax	5	5	1	-1
	25	17	12	6	4
YOY Profit Growth %		-33.00%	-29.91%	-49.21%
EPS in Rs	5.13	3.44	2.41	1.22	0.85
Dividend Payout %	0%	0%	0%	1%

Compounded Sales Growth

3 Years:: -2%
TTM:: 7%

Compounded Profit Growth

3 Years:: -38%
TTM:: -59%

Stock Price CAGR

3 Years:: 6%
1 Year:: 109%

Return on Equity

4 Years:: 7%
Last Year:: 2%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	49	49	49	54
Reserves	152	190	204	243
	62	112	118	126
Long term borrowings	25	36	40	42
Short term borrowings	35	71	72	81
	79	96	102	117
Trade payables	58	62	70	73
Minority interest		0	0	0
Current liabilities	111	159	166	190
Total Liabilities	342	447	472	539
	122	180	202	215
Gross block	196	268	294	322
Accumulated depreciation	74	87	92	106
Goodwill & intangibles	14	23	32	42
CWIP	18	24	44	59
	202	243	226	265
Inventories	54	81	86	94
Trade receivables	95	100	107	109
Cash & equivalents	6	10	2	25
Current assets	191	228	231	276
Total Assets	342	447	472	539

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	38	16	41	50
Profit for the year	24	17	12	6
Working capital changes	-12	-27	-12	16
Direct taxes paid	-7	-3	1	-4
	-36	-73	-40	-56
Fixed assets purchased	-37	-74	-41	-44
Fixed assets sold	0	1	1	6
Investments purchased		-0	-0	-21
Investments sold	0	1	0	3
	1	60	-9	28
Proceeds from borrowings	18	28	25	22
Repayment of borrowings	-15	-13	-15	-21
Interest paid	-6	-8	-12	-13
Dividends paid	-0	-0	-0	-0
Net Cash Flow	3	3	-8	21
Free Cash Flow	2	-58	0	5

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	12.2%	7.9%	5.0%	2.1%
ROCE	17.5%	10.3%	9.2%	5.8%
Operating margin	9.1%	7.5%	7.3%	3.1%
Net margin	6.3%	4.9%	3.4%	1.6%
Debt / equity	0.31	0.47	0.47	0.43
Current ratio	1.72	1.43	1.39	1.45
Debtor days	89	103	108	111
Inventory days	98	172	187	206
Days payable	106	132	150	160
Cash conversion cycle	81	143	145	157
Working capital days	75	70	65	87

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 30.30%
FIIs 0.17%
DIIs 1.19%
Public 68.34%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	30.35%	30.36%	30.30%
		0.01%			0.21%	0.01%	0.03%		0.02%		0.03%	0.17%
Foreign portfolio investors (Cat. I)		0.01%			0.16%	0.01%	0.03%		0.02%		0.03%	0.05%
Foreign portfolio investors (Cat. II)					0.05%							0.12%
			0.11%	0.10%	0.24%	0.24%	0.24%	0.24%	0.20%	0.07%	1.33%	1.19%
Mutual funds											1.07%	1.18%
Alternative investment funds					0.16%	0.16%	0.16%	0.16%	0.12%		0.27%	0.01%
	66.74%	66.73%	66.63%	66.63%	66.28%	66.49%	66.46%	66.51%	66.52%	69.58%	68.28%	68.34%
Retail (up to ₹2 lakh)	18.53%	18.51%	19.08%	18.85%	17.94%	18.57%	17.62%	18.71%	18.65%	16.67%	14.42%	13.45%
HNIs (above ₹2 lakh)	32.39%	30.50%	30.13%	26.63%	26.45%	29.21%	29.88%	29.49%	17.97%	16.10%	17.40%	17.59%
NRIs	1.55%	1.66%	1.71%	1.82%	1.75%	1.81%	1.75%	2.02%	2.14%	1.94%	2.07%	2.08%
Bodies corporate	4.22%	6.70%	6.18%	10.10%	10.70%	7.54%	7.88%	6.78%	18.11%	17.06%	16.85%	17.89%
IEPF	3.03%	3.03%	3.03%	3.03%	3.59%	3.59%	3.58%	3.58%	3.97%	3.60%	3.58%	3.57%
No. of Shareholders	17,342	17,100	17,483	17,716	17,450	17,448	16,641	17,282	17,251	16,636	14,510	13,057

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding ZIM Laboratories

Holder (above 1%)	Stake
Tata India Pharma & Healthcare FundMutual fund	1.18%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 1.18% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 1 Jan 1970
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

No recent coverage found.

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about ZIM Laboratories Limited

What is the share price of ZIM Laboratories Limited today?

ZIM Laboratories Limited (ZIMLAB) last traded at ₹144.76 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of ZIM Laboratories Limited?

About ₹775 crore at the latest price.

What is the P/E ratio of ZIM Laboratories Limited?

About 176.5 times its earnings over the last 12 months.

Is ZIM Laboratories Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy ZIM Laboratories Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

ZIM Laboratories Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About ZIM Laboratories Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding ZIM Laboratories

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about ZIM Laboratories Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next